Assignee
MICROMET AG
DE·20 granted patents·9 pending applications·1,450 citations·filing 1993–2009
Top patents by PatentIndex Score
29 records- 0197US7820166B2Potent T cell modulating moleculesMICROMET AG·Filed 2003·Granted Oct 26, 2010·94 cites·30 claims
- 0297US7235641B2Bispecific antibodiesMICROMET AG·Filed 2003·Granted Jun 26, 2007·167 cites·2 claims
- 0396US8007796B2Means and methods for the treatment of tumorous diseasesMICROMET AG·Filed 2006·Granted Aug 30, 2011·69 cites·18 claims
- 0496US7635472B2Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disordersMICROMET AG·Filed 2004·Granted Dec 22, 2009·158 cites·8 claims
- 0595US7575923B2CD19xCD3 specific polypeptides and uses thereofMICROMET AG·Filed 2006·Granted Aug 18, 2009·103 cites·4 claims
- 0694US7632925B2Antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 2007·Granted Dec 15, 2009·17 cites·10 claims
- 0794US7112324B1CD 19×CD3 specific polypeptides and uses thereofMICROMET AG·Filed 1999·Granted Sep 26, 2006·219 cites·23 claims
- 0892US8017748B2Antibody neutralizers of human granulocyte macrophage colony stimulating factorMICROMET AG·Filed 2006·Granted Sep 13, 2011·56 cites·20 claims
- 0992US7919089B2Pharmaceutical composition comprising a bispecific antibody for EpCAMMICROMET AG·Filed 2004·Granted Apr 5, 2011·57 cites·3 claims
- 1092US6723538B2Bispecific antibody and chemokine receptor constructsMICROMET AG·Filed 2001·Granted Apr 20, 2004·149 cites·11 claims
- 1191US7332168B2Composition for the elimination of autoreactive B-cellsMICROMET AG·Filed 2001·Granted Feb 19, 2008·42 cites·2 claims
- 1288US7323440B2De-immunized MOG (poly)peptide constructsMICROMET AG·Filed 2003·Granted Jan 29, 2008·41 cites·8 claims
- 1388US7229760B2mRNA amplificationMICROMET AG·Filed 2001·Granted Jun 12, 2007·72 cites·40 claims
- 1483US7976842B2Treatment of metastatic breast cancerMICROMET AG·Filed 2007·Granted Jul 12, 2011·7 cites·6 claims
- 1582US7435549B1Method of identifying binding site domains that retain the capacity of binding to an epitopeMICROMET AG·Filed 1998·Granted Oct 14, 2008·51 cites·47 claims
- 1682US7227002B1Human antibodies that bind human 17-A1/EpCAM tumor antigenMICROMET AG·Filed 1998·Granted Jun 5, 2007·52 cites·10 claims
- 1778US6673541B1DNA amplification of a single cellMICROMET AG·Filed 1999·Granted Jan 6, 2004·92 cites·30 claims
- 1871US7964707B2Anti-IL2 antibodiesMICROMET AG·Filed 2006·Granted Jun 21, 2011·2 cites·19 claims
- 1963US2010183615A1Cross-species-specific bispecific bindersMICROMET AG·Filed 2008·Application pending·0 cites
- 2060US2011262440A1Treatment of pediatric acute lymphoblastic leukemiaMICROMET AG·Filed 2009·Application pending·0 cites
- 2158US2003148463A1Novel method for the production of anti-human antigen receptors and uses thereofMICROMET AG·Filed 2002·Application pending·0 cites
- 2254US2009226444A1Pharmaceutical antibody compositions with resistance to soluble ceaMICROMET AG·Filed 2006·Application pending·0 cites
- 2349US2010150918A1Cross-species-specific binding domainMICROMET AG·Filed 2008·Application pending·0 cites
- 2445US2007122852A1Method for identifying antigen specific b cellsMICROMET AG·Filed 2003·Application pending·0 cites
- 2543US2009241202A1Domain-grafted antibodiesMICROMET AG·Filed 2006·Application pending·0 cites
- 2642US2005180979A1Anti-EpCAM immunoglobulinsMICROMET AG·Filed 2004·Application pending·0 cites
- 2741US2007274982A1Anti-EpCam ImmunoglobulinsMICROMET AG·Filed 2005·Application pending·0 cites
- 2832US6475727B1Primers and methods for the detection of disseminated tumor cellsMICROMET AG·Filed 1998·Granted Nov 5, 2002·2 cites·20 claims
- 2931US7105638B1Product and process for the production, isolation, and purification of recombinant polypeptideMICROMET AG·Filed 1993·Granted Sep 12, 2006·0 cites·18 claims
Join the waitlist — get patent alerts
Get an alert when MICROMET AG files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →